Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  Issue: February 2021  |  February 16, 2021

Follow-Up Studies

Follow-up studies by Dr. Steen and others proved that ACE inhibitors were a life­saving intervention. Dr. Steen et al. reported on the experience of 108 patients who had scleroderma renal crisis between 1972 and 1985. The one-year survival after scleroderma renal crisis was 76% in patients who had taken ACE inhibitors and only 15% in those who had not.11 Though some patients still died and other required permanent dialysis, renal crisis could usually be effectively managed when treated early and aggressively with ACE inhibitors. More than half of the patients who initially required dialysis were able to come off it if they continued taking ACE inhibitors while their kidneys healed. 

Currently, early intervention with ACE inhibitors is the standard of care at first sign of scleroderma renal crisis. However, other applications of ACE inhibitors in scleroderma patients are not as clear. Researchers also explored the role of these drugs as agents to prevent scleroderma renal crisis. By this time, ACE inhibitors were already being prescribed as a preventative for diabetic kidney disease. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, some studies suggested that ACE inhibitors used as a preventative for scleroderma renal crisis might worsen outcomes, particularly if given to patients with normal blood pressure.12 This created some confusion in the field.

Some researchers expressed concern that ACE inhibitors might mask hypertension and lead to delayed diagnosis of renal crisis.13 Dr. Steen speculates that the chronic administration of an ACE inhibitor might have changed the disease course in some of these patients. She says, “They were presenting with creatinines that were 3 and 4 instead of 1 or 2, and by that time they already had chronic kidney disease.” 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Some practitioners still prescribe ACE inhibitors as first-line agents for managing essential hypertension in scleroderma patients if they are not in a high-risk group. In contrast, Dr. Whitman notes, “As a rule of thumb, we don’t give diuretics to scleroderma patients unless we are forced to—for example, if they have heart failure—because you could theoretically trigger the renin-angiotensin system and scleroderma renal crisis.” He adds that he might start a patient out on calcium channel blocker, which are particularly good for Raynaud’s symptoms. “But if the blood pressure kept going up, we might give them an ACE inhibitor or an [angiotensin II receptor blocker].” 

Scientists still have questions about renal disease in settings other than scleroderma renal crisis. Some patients have essential hypertension unrelated to scleroderma, or they have renal disease from other medical conditions. Additionally, many patients with scleroderma have subtle renal abnormalities, such as proteinuria and involvement of renal vessels, though these changes seem not to predict the development of scleroderma renal crisis.12 Dr. Steen points out that although some might develop mild renal insufficiency, very few patients go on to develop renal failure unless they experience a true scleroderma renal crisis. 

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Related Articles
    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Can Technology Help Solve Scleroderma Renal Crisis?

    December 1, 2010

    A case study in using the Internet to facilitate rare disease research

    Case Report: A Patient Develops Scleroderma Renal Crisis

    October 18, 2019

    Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences